Sign in to view content

Open-Label Study Evaluating the Effects of the CCR3 Antagonist ALK4290 in Patients With Neovascular AMD Refractory to Anti-VEGF Therapy

Michael W. Stewart, MD

Video
Published 2019

Michael W. Stewart, MD

AMD Neovascular Part II Symposium

Related

Two-Year Results of an Ongoing Phase 1b/2 Open-Label Clinical Trial of AU-011 for the Primary Treatment of Small to Medium Choroidal Melanoma
Amy C. Schefler, MD FACS FASRS
Annual Meeting Talks
2019
Endophthalmitis After Intravitreal Injection of Vascular Endothelial Growth Factor (VEGF) Inhibitors: Management and Visual Outcomes
Kunyong Xu, MD, MHSc
Annual Meeting Talks
2018
Time to Dry Analysis of Brolucizumab Versus Aflibercept in Patients With Neovascular AMD: 96-Week Data From HAWK and HARRIER Trials
Carl D. Regillo, MD
Annual Meeting Talks
2019

Category: AMD-Neovascular

See more